Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of dual bronchodilation with umeclidinium/vilanterol on patients with COPD, hyperinflation and heart failure
2024-519513-61-00Phase 4Authorised
- Sponsor
- Gregorio Marañón University General Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Anoro Ellipta in chronic obstructive pulmonary disease (COPD) and heart failure with mid-range ejection fraction (HFmrEF) (2 arms), sponsored by Gregorio Marañón University General Hospital. Primary endpoints: Baseline-corrected time-velocity integral during peak exercise and Maximal oxygen pulse on cardiopulmonary exercise test. Planned start Nov 2024; status: authorised.
02
Drugs
Anoro Ellipta
03
Conditions
chronic obstructive pulmonary disease (COPD)heart failure with mid-range ejection fraction (HFmrEF)
Beyond the preview
Go deeper on 2024-519513-61-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519513-61-00.